Single Ascending Dose Study Investigating the Safety, Tolerability, and PK of XC130-A10H in Healthy Adult Subjects

• Status: Active, not recruiting
• Trial end date: 2022-04-30
• Target enrollment: 0
• Participant gender: All

Summary

This is a randomized, double-blind, placebo-controlled, parallel-group single ascending dose (SAD) study. Up to 5 cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation. In each cohort, subjects will receive a single oral dose of XC130-A10H or matching placebo on Day 1. Safety, tolerability, and pharmacokinetics will be assessed throughout the study. Dose escalation will not take place until the Principal Investigator, Sponsor, and Medical Monitor have determined that adequate safety and tolerability from the previous cohorts have been demonstrated to permit proceeding to the next cohort.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Xoc Pharmaceuticals
• Collaborator: Celerion

Criteria

Major Inclusion Criteria:

• Healthy, adult, male or female of non-childbearing potential only, 18-75 years of age.

• Body mass index (BMI) ≥ 18 and ≤ 32.0 kg/m2 at screening.

• Medically healthy with no clinically significant findings from medical history, physical examination, laboratory profiles, vital signs or ECGs.

• Understands the study procedures in the informed consent form (ICF), and is willing and able to comply with the protocol.

Major Exclusion Criteria:

• Mental or legal incapacitation or significant emotional problems either present at the time of the screening visit or expected during the conduct of the study.

• History or presence of clinically significant medical, surgical or psychiatric condition or disease.

• History of any illness that, in the opinion of the PI, might confound the results of the study or poses an additional risk to the subject by their participation in the study.

• History of clinically significant hypotension.

• History of orthostatic hypotension in the 12 months prior to screening.

• Clinically significant hypertension at screening.

• History or presence of alcoholism within the 2 years prior to dosing or any history of drug abuse.